Please login to the form below

Not currently logged in
Email:
Password:

MSD submits sarcoma drug for US approval

MSD has asked the US Food and Drug Administration to consider its oral mTOR inhibitor, ridaforolimus, for approval in the treatment of sarcomas – a cancer of the body's connective tissue

MSD has asked the US Food and Drug Administration (FDA) to consider its oral mTOR inhibitor, ridaforolimus, for approval in the treatment of patients with metastatic soft tissue or bone sarcomas in patients who had a favourable response to chemotherapy.

The therapy has already been submitted to the European Medicines Agency (EMA) for approval.

Sarcomas are a group of cancers of connective tissue of the body for which there are currently limited treatment options.

MSD obtained full rights to ridaforolimus in May 2010 in an agreement with its initial developers, ARIAD Pharmaceuticals, for an upfront payment of $50m plus additional milestone payments.

ARIAD agreed to co-promote the drug in the US if it is approved.

6th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Emma Walmsley 2
30 women leaders in UK healthcare (part 3)
Part 3 of our list of thirty women leaders...
Louise Houson
30 Women Leaders in UK Healthcare
The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future...
Ingrid
30 Women Leaders in UK Healthcare (part 2)
Part two of our list of thirty women leaders 11-20...

Infographics